Back to Search Start Over

Tumor vessel co-option probed by single-cell analysis.

Authors :
Teuwen LA
De Rooij LPMH
Cuypers A
Rohlenova K
Dumas SJ
García-Caballero M
Meta E
Amersfoort J
Taverna F
Becker LM
Veiga N
Cantelmo AR
Geldhof V
Conchinha NV
Kalucka J
Treps L
Conradi LC
Khan S
Karakach TK
Soenen S
Vinckier S
Schoonjans L
Eelen G
Van Laere S
Dewerchin M
Dirix L
Mazzone M
Luo Y
Vermeulen P
Carmeliet P
Source :
Cell reports [Cell Rep] 2021 Jun 15; Vol. 35 (11), pp. 109253.
Publication Year :
2021

Abstract

Tumor vessel co-option is poorly understood, yet it is a resistance mechanism against anti-angiogenic therapy (AAT). The heterogeneity of co-opted endothelial cells (ECs) and pericytes, co-opting cancer and myeloid cells in tumors growing via vessel co-option, has not been investigated at the single-cell level. Here, we use a murine AAT-resistant lung tumor model, in which VEGF-targeting induces vessel co-option for continued growth. Single-cell RNA sequencing (scRNA-seq) of 31,964 cells reveals, unexpectedly, a largely similar transcriptome of co-opted tumor ECs (TECs) and pericytes as their healthy counterparts. Notably, we identify cell types that might contribute to vessel co-option, i.e., an invasive cancer-cell subtype, possibly assisted by a matrix-remodeling macrophage population, and another M1-like macrophage subtype, possibly involved in keeping or rendering vascular cells quiescent.<br />Competing Interests: Declaration of interest The authors declare no competing interests.<br /> (Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.)

Details

Language :
English
ISSN :
2211-1247
Volume :
35
Issue :
11
Database :
MEDLINE
Journal :
Cell reports
Publication Type :
Academic Journal
Accession number :
34133923
Full Text :
https://doi.org/10.1016/j.celrep.2021.109253